Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy

Breast Cancer Research and Treatment

Volumn 151, Issue 1, 2015, Pages 149-156

  Enewold, Lindsey ^a   Geiger, Ann M ^a   Zujewski, JoAnne ^a   Harlan, Linda C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Chemotherapy, adjuvant; Female; SEER; Tumor markers, biological *genetics

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; TUMOR MARKER; TUMOR PROTEIN;

21 GENE RECURRENCE SCORE ASSAY; ADULT; AGE; AGED; ARTICLE; BIOASSAY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER STAGING; DIAGNOSTIC KIT; ETHNICITY; FEMALE; HEALTH INSURANCE; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MIDDLE AGED; POPULATION RESEARCH; PRIORITY JOURNAL; SOCIAL STATUS; TREND STUDY; UNITED STATES; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; BREAST NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN; UNITED STATES;

EID: 84928559766     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3366-7     Document Type: Article

References (33)

1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 18 Regs Research Data+Hurricane Katrina Impacted Louisiana Cases, Nov 2012 Sub (2000–2010) Katrina/Rita population adjustment: linked to county attributes—total U.S., 1969–2011 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. Released on April 2013, Submitted on November 2012
2. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826
3. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A, Fulton S, Hendricks CB, Kemeny M, Kornblith AB et al (2001) National institutes of health consensus development conference statement: adjuvant therapy for breast cancer. J Natl Cancer Inst 93:979–989
4. Baker J (2007) Genomic health, Inc. Pharmacogenomics 8(4):397–399
5. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734
6. Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K (2010) Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer 116(13):3112–3118
7. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312
8. National Comprehansive Cancer Network. NCCN Clinical practice guidelines in oncology: breast cancer. V 1.2014. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#breast Accessed Nov 2013
9. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE et al (2008) Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063–4071
10. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55–65
11. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A et al (2010) Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 28:1829–1834
12. ClinicalTrials.gov. Tamoxifen citrate, Letrozole, anastrozole, or exemestane with or without chemotherapy in treating patients with invasive RxPONDER breast cancer. http://clinicaltrials.gov/ct2/show/NCT01272037?term=RxPONDER&rank=1 Accessed May 2014
13. Haas JS, Liang SY, Hassett MJ, Shiboski S, Elkin EB, Phillips KA (2011) Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Breast Cancer Res Treat 130(2):619–626
14. Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, Hudis CA, Marcom PK, Pettinga JE, Share D et al (2012) Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 30(18):2218–2226
15. Lund MJ, Mosunjac M, Davis KM, Gabram-Mendola S, Rizzo M, Bumpers HL, Hearn S, Zelnak A, Styblo T, O’Regan RM (2012) 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Cancer 118(3):788–796
16. Chen C, Dhanda R, Tseng WY, Forsyth M, Patt DA (2013) Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer. J Oncol Pract/Am Soc Clin Oncol 9(4):182–187
17. DeFrank JT, Salz T, Reeder-Hayes K, Brewer NT (2013) Who gets genomic testing for breast cancer recurrence risk? Public Health Genom 16(5):215–222
18. Carlson JJ, Roth JA (2013) The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat 141(1):13–22
19. Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, Hortobagyi GN, Pusztai L (2010) Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116(22):5161–5167
20. National Cancer Institute. SEER registry groupings for analyses. http://seer.cancer.gov/registries/terms.html Accessed 05/07/2013
21. Breast (2010) In: Edge SB, Byrd DR, Compton CC et al., (eds) AJCC cancer staging manual 7th ed, Springer, New York, pp 347–376. http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional/page3
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
23. National Cancer Institute. Surveillance, epidemiology, and end results program (2014) Race recode changes. http://seer.cancer.gov/seerstat/variables/seer/race_ethnicity/ Accessed Aug 2014
24. American Hospital Association: American Hospital Association Annual Survery Database. http://www.aha.org/research/rc/stat-studies/data-and-directories.shtml
25. Genomic Health (2014) Press release: medicare contractor establishes reimbursement coverage policy for genomic health’s Oncotype DX(TM) breast cancer test. http://investor.genomichealth.com/releaseDetail.cfm?releaseID=184309 Accessed Aug 2014
26. Genomic Health (2014) Press release: genomic health announces national agreement with Aetna. http://investor.genomichealth.com/releasedetail.cfm?ReleaseID=219910 Accessed Aug 2014
27. BlueCross BlueShield of Mississippi (2014) Assays of genetic expression in tumor tissue as a technique to determine prognosis in patients with breast cancer. https://www.bcbsms.com/index.php?q=provider-medical-policy-search.html&action=viewPolicy&path=%2Fpolicy%2Femed%2FAssays_of_Genetic_Expression_in_Tumor_Tissue_as_a_Technique_to_Determine_Prognosis_in_Patients_with_Breast_Cancer.html Accessed Aug 2014
28. BlueCross BlueShield of North Carolina (2014) Assays of genetic expression to determine prognosis of breast cancer. http://www.bcbsnc.com/assets/services/public/pdfs/medicalpolicy/assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer.pdf Accessed Aug 2014
29. UnitedHealthcare Medicare Advantage Plans (2014) Coverage summary: genetic testing. https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/Policies%20and%20Protocols/UnitedHealthcare%20Medicare%20Coverage/Genetic_Testing_SH_Ovations.pdf. Accessed Aug 2014
30. UnitedHealthcare. Molecular pathology/molecular diagnostics/genetic testing. https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Main%20Menu/Tools%20&%20Resources/Policies%20and%20Protocols/Medicare%20Advantage%20Reimbursement%20Policies/M/MolecularGeneticTest_01252013.pdf. Accessed Aug 2014
31. Genomic Health, Inc. (2013) Oncotype Dx FAQs: http://www.mybreastcancertreatment.org/en-US/AboutOncotypeDX/OncotypeDXFAQs.aspx#fbac3992-b9cd-489a-a325-9e84bb78f9af Accessed Dec 2013
32. Zujewski JA, Kamin L (2008) Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol 4(5):603–610
33. ClinicalTrials.gov. (2013) Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for node-negative breast cancer (The TAILORx Trial) http://clinicaltrials.gov/show/NCT00310180 Accessed Dec 2013